StockNews.com Begins Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP)

StockNews.com started coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research report sent to investors on Friday morning. The brokerage issued a hold rating on the stock.

Tonix Pharmaceuticals Trading Up 0.2 %

Tonix Pharmaceuticals stock opened at $0.24 on Friday. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81. The company has a market capitalization of $44.01 million, a price-to-earnings ratio of 0.00 and a beta of 2.02. Tonix Pharmaceuticals has a one year low of $0.12 and a one year high of $12.48. The company’s fifty day moving average price is $0.26 and its two-hundred day moving average price is $0.30.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($2.03) by $1.80. The firm had revenue of $2.82 million for the quarter, compared to the consensus estimate of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. On average, analysts forecast that Tonix Pharmaceuticals will post -17.63 earnings per share for the current fiscal year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.